Ikena Oncology (IKNA) Competitors $1.42 +0.05 (+3.65%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$1.34 -0.08 (-5.92%) As of 07:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IKNA vs. ZYBT, TKNO, SGMT, CRVS, CRDF, TSVT, ALLO, TNXP, CADL, and INZYShould you be buying Ikena Oncology stock or one of its competitors? The main competitors of Ikena Oncology include Zhengye Biotechnology (ZYBT), Alpha Teknova (TKNO), Sagimet Biosciences (SGMT), Corvus Pharmaceuticals (CRVS), Cardiff Oncology (CRDF), 2seventy bio (TSVT), Allogene Therapeutics (ALLO), Tonix Pharmaceuticals (TNXP), Candel Therapeutics (CADL), and Inozyme Pharma (INZY). These companies are all part of the "pharmaceutical products" industry. Ikena Oncology vs. Its Competitors Zhengye Biotechnology Alpha Teknova Sagimet Biosciences Corvus Pharmaceuticals Cardiff Oncology 2seventy bio Allogene Therapeutics Tonix Pharmaceuticals Candel Therapeutics Inozyme Pharma Zhengye Biotechnology (NASDAQ:ZYBT) and Ikena Oncology (NASDAQ:IKNA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability. Do analysts prefer ZYBT or IKNA? Ikena Oncology has a consensus price target of $3.00, suggesting a potential upside of 111.27%. Given Ikena Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Ikena Oncology is more favorable than Zhengye Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Ikena Oncology 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is ZYBT or IKNA more profitable? Zhengye Biotechnology's return on equity of 0.00% beat Ikena Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Zhengye BiotechnologyN/A N/A N/A Ikena Oncology N/A -30.59%-27.55% Do institutionals & insiders have more ownership in ZYBT or IKNA? 75.0% of Ikena Oncology shares are held by institutional investors. 5.9% of Ikena Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media favor ZYBT or IKNA? In the previous week, Ikena Oncology had 4 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 5 mentions for Ikena Oncology and 1 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 1.89 beat Ikena Oncology's score of 0.98 indicating that Zhengye Biotechnology is being referred to more favorably in the media. Company Overall Sentiment Zhengye Biotechnology Very Positive Ikena Oncology Positive Which has preferable earnings & valuation, ZYBT or IKNA? Zhengye Biotechnology has higher revenue and earnings than Ikena Oncology. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZhengye Biotechnology$25.53M10.27N/AN/AN/AIkena Oncology$9.16M7.48-$49.23M-$0.86-1.65 SummaryIkena Oncology beats Zhengye Biotechnology on 6 of the 11 factors compared between the two stocks. Get Ikena Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for IKNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IKNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IKNA vs. The Competition Export to ExcelMetricIkena OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$66.11M$2.96B$5.61B$9.29BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-1.6520.2228.5419.58Price / Sales7.48299.17429.2495.01Price / CashN/A43.1536.0257.93Price / Book0.547.568.145.54Net Income-$49.23M-$55.11M$3.24B$257.73M7 Day Performance5.97%3.81%0.18%-0.08%1 Month Performance0.71%11.60%5.96%8.09%1 Year Performance-17.68%-2.11%26.24%13.02% Ikena Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IKNAIkena Oncology2.7708 of 5 stars$1.42+3.6%$3.00+111.3%-16.5%$66.11M$9.16M-1.6570News CoverageGap UpHigh Trading VolumeZYBTZhengye BiotechnologyN/A$5.73+3.4%N/AN/A$270.26M$189.75M0.00278Positive NewsGap UpTKNOAlpha Teknova2.0293 of 5 stars$5.06+1.3%$8.50+68.2%+243.8%$269.34M$37.74M-10.50240Positive NewsSGMTSagimet Biosciences2.8212 of 5 stars$8.75+0.8%$26.60+204.0%+179.1%$268.33M$2M-4.978Positive NewsCRVSCorvus Pharmaceuticals2.8416 of 5 stars$3.94+0.9%$15.00+281.2%+108.5%$267.91MN/A-4.0130Positive NewsCRDFCardiff Oncology1.2399 of 5 stars$4.03+10.3%$11.70+190.7%+64.1%$266.79M$680K-4.3620TSVT2seventy bioN/A$5.00flat$5.00N/A$266.15M$48.37M-2.69440ALLOAllogene Therapeutics3.6338 of 5 stars$1.22+4.7%$8.44+595.0%-58.4%$263.57M$20K-0.98310Positive NewsTNXPTonix Pharmaceuticals2.6681 of 5 stars$35.22-0.6%$585.00+1,561.0%-25.9%$258.49M$10.04M-0.0250Gap UpCADLCandel Therapeutics2.482 of 5 stars$5.18+3.7%$22.00+325.1%-5.6%$258.28MN/A-3.8560Positive NewsAnalyst RevisionINZYInozyme Pharma3.4877 of 5 stars$4.00flat$11.75+193.8%N/A$258.25MN/A-2.3750 Related Companies and Tools Related Companies ZYBT Competitors TKNO Competitors SGMT Competitors CRVS Competitors CRDF Competitors TSVT Competitors ALLO Competitors TNXP Competitors CADL Competitors INZY Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IKNA) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDrilling With a $3.5B Discovery Partner in Its CornerA small-cap explorer is about to drill for high-grade gold in a region known for multi-million-ounce discoveri...The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ikena Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ikena Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IKNA Stock Alerts